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ABSTRACT
Background. It is clearly established that emotional events tend to be remembered particularly
vividly. The neurobiological substrates of this phenomenon are poorly understood. Recently, the
noradrenergic system has been implicated in that beta blockade has been shown to reduce
significantly the delayed recall of emotional material with matched neutral material being
unaffected.
Methods. In the present study, 36 healthy young adults were randomly allocated to receive either
yohimbine, which stimulates central noradrenergic activity, metoprolol which blocks noradrenergic
activity, or matched placebo. The three groups were well matched. All capsules were taken orally,
prior to viewing a narrated 11 slide show described a boy being involved in an accident.
Results. Yohimbine significantly elevated, and metoprolol reduced mean heart rate during the slide
show relative to placebo, thus confirming the efficacy of the pharmacological manipulation. One
week later, in a ‘surprise ’ test, memory for the slide show was tested. As predicted, yohimbine-
treated subjects recalled significantly more and metoprolol subjects fewer slides relative to placebo.
This result was confirmed via analysis of multiple-choice recognition memory scores.
Conclusions. We conclude that stimulation of the noradrenergic system results in the enhancement
and blockade in a reduction of recall and recognition of emotional material in man.
INTRODUCTION
It is clearly established that emotional events
tend to be remembered particularly vividly
(Christianson, 1992). Over a century ago, Wil-
liam James stated ‘An experience may be so
exciting emotionally as almost to leave a scar on
the cerebral tissues ’ (James, 1884). A recent
demonstration of this phenomenon was reported
by Ikeda et al. (1998), who studied 51 Alzheimer
patients who had experienced the Kobe earth-
quake in Japan and were studied 6 to 10 weeks
after the disaster. All had received an MRI brain
scan in the intervening period. It was hypothe-
" Address for correspondence: Professor R. E. O’Carroll, School of
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sized that both events would be highly mem-
orable, but that the earthquake would have
evoked significantly more emotion than the
MRI. The earthquake was remembered by
86–3% of the subjects, however, only 31–4%
remembered having the MRI scan. This study is
an example of the phenomena whereby emotion
reinforces memory for an event, even in subjects
with compromised memories.
In recent years, there has been a renaissance in
the study of emotion in cognitive neuroscience
(LeDoux, 1996; Cahill & McGaugh, 1998).
While it has been well recognized that emotional
experiences are often remembered particularly
vividly, the underlying neurobiological mech-
anisms responsible for this phenomenon have
been poorly understood. Cahill et al. (1994)
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demonstrated that beta-adrenergic activity was
involved in memory for emotive material in
humans. Healthy young adults were shown a
series of slides with either a neutral or arousing
accompanying narrative. In the central section
of the arousing slide show, a boy has a serious
car crash, is nearly killed, and has to have his
feet surgically reattached. Half the subjects
received a single 40 mg capsule of the beta
blocker propranolol, 1 h before the slide pres-
entation and the other half received placebo.
One week later in a ‘surprise ’ memory test,
Cahill et al. (1994) showed that the beta blockade
had selectively impaired recall and recognition
for the emotive central story section in the
propranolol-treated subjects. Further studies
have implicated the amygdala in this system
(Cahill et al. 1995, 1996). Subsequent attempts
to replicate the Cahill et al. (1994) beta blockade
study have produced conflicting results (van
Stegeren et al. 1998; O’Carroll et al. 1999). The
present study attempted to test the hypothesis
that stimulation of the central noradrenergic
system would result in an enhancement, and
blockade in a reduction, of memory for emo-
tional material in man.
METHOD
Thirty-six healthy young adults were recruited
from local universities. They were told that we
were interested in their physiological and sub-
jective responses to arousing material. All
subjects gave informed consent and the study
was approved by the University and local Health
Service NHS Trust Ethics Committees. Pro-
spective subjects were told that they would
participate in the experiment which would
consist of two sessions, 1 week apart, and they
were asked not to discuss the study with anyone
in the intervening week. Subjects were randomly
allocated to one of three conditions : (a) 20 mg
yohimbine hydrochloride, which stimulates cen-
tral noradrenergic activity via blockade of the
alpha-2 adrenergic autoreceptor (Charney et al.
1987; Peskind et al. 1995) ; (b) 50 mg metoprolol,
a widely used clinical beta blocker, (selective to
the beta-1 receptor (Walker, 1991)) ; or (c)
matched placebo. The subjects were all assessed
for the potential confounding variables of age,
sex, intelligence (Nelson & Willison, 1991)
general memory functioning (Delis et al. 1987),
extroversion and neuroticism (Eysenck et al.
1985), basal blood pressure and pulse rate.
Procedure
All capsules were taken orally 90 min prior to
viewing a narrated 11 slide show in a double-
blind design. This time was selected so as to allow
for peak plasma drug levels at time of stimulus
exposure (Peskind et al. 1995; Walker, 1991). In
this experiment, only the emotionally arousing
narrative was used. The slides and story describe
a boy being involved in an accident with the
emotional story elements being introduced in
the central phase of the slide show (Cahill et al.
1994; Cahill & McGaugh, 1995). All subjects
had continuous heart monitoring throughout
the narrated slide show using the Biopac MP30
system. Immediately following the slide show,
subjects rated their personal emotional reactions
to the slides, using an 0–10 scale, following
Cahill et al. (1994). One week following the
initial phase of the study, subjects returned to
the laboratory and were told that, in fact, the
focus of the study was memory for the material
that was presented the previous week. They were
asked to recall freely as much as they could of
the slides and story. Thereafter, they were told
that they, in fact, had seen 11 slides and were
asked to describe as many of the slides as they
could remember seeing. They were then given a
multiple choice test regarding their detailed
memory for each slide. Five to nine questions
per slide were asked, following Cahill et al.
(1994), for example: ‘Whose picture is in slide
1? ’ (a) mother and her son; (b) father and his
son; (c) mother and father ; (d ) no one is
pictured. Scoring was conducted with the ex-
perimenter blind to drug condition. All subjects
were asked whether they had guessed the
memory would be assessed at the second session,
and none indicated that they had. Full details of
the methodology are provided by in Cahill et al.
(1995) and Cahill & McGaugh (1995).
Statistical analysis
Between-group differences in matching variables
were tested for using ANOVA and chi-square
statistics. For the main experimental hypothesis,
we predicted an ordered effect, namely that
yohimbine would stimulate noradrenergic func-
tion and metoprolol would block noradrenergic
function, relative to placebo. We, therefore,
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predicted an ordered effect of yohimbine"
placebo"metoprolol and accordingly em-
ployed the Jonckheere non-parametric trend test
as the principal test of our experimental hy-
pothesis (Coolican, 1994), thus obviating the
need for post hoc comparisons.
RESULTS
No significant differences emerged between the
three subject groups in terms of any of potential
confounding variables (see Table 1). There was
no significant difference between the groups in
mean (s.d.) number of days elapsed between
slide presentation and memory test (metoprolol
6–4 (0–9) days, yohimbine 6–7 (1–9) days and pla-
cebo 6–6 (1–2) days, Ffl 0–93, Pfl 0–91. Yohim-
bine significantly elevated and metoprolol re-
duced mean heart rate during the slide show,
relative to placebo, thus confirming the efficacy
of the pharmacological manipulation (metopro-
lolfl 53–8 (8–1), placebofl 63–8 (11–8), yohim-
binefl 71–6 (10–8), Jonckheere Zfl 3–85, P!
0–0001). Immediately following the slide pres-
entation, there was no significant between-group
difference in subjective emotional reaction to the
story and slides recorded using a 0–10 scale,
following Cahill et al. (1994) : metoprolol rating
meanfl 3–8, standard deviationfl 2–1; placebo
fl 4–7 (1–9), yohimbinefl 4–5 (2–8), Ffl 0–53,
Pfl 0–59.
Table 1. Three groups matched on potential confounding variables
Metoprolol
Nfl 12
Mean (s.d.)
Yohimbine
Nfl 12
Mean (s.d.)
Placebo
Nfl 12
Mean (s.d.) F P
Age 21–1 (2–7) 23–2 (7–5) 21–3 (2–2) 0–698 0–505
CVLT (1–5) 59–1 (7–0) 58–4 (7–8) 58–1 (10–1) 0–044 0–957
CVLT del 13–8 (2–7) 13–2 (2–5) 13–4 (2–2) 0–218 0–806
CVLT disc 97–8 (3–2) 97–3 (3–6) 98–1 (2–8) 0–213 0–809
NART IQ 111–6 (7–6) 110–8 (7–8) 110–7 (8–7) 0–043 0–958
N 12–0 (6–0) 10–7 (5–9) 7–8 (3–6) 1–939 0–159
E 17–5 (2–4) 16–0 (4–7) 16–1 (2–8) 0–722 0–493
P 4–4 (3–3) 3–8 (1–9) 3–5 (2–1) 0–411 0–667
L 4–0 (1–8) 5–8 (2–9) 6–5 (2–5) 3–409 0–045
Pre Sys 121–6 (13–7) 125–3 (9–7) 121–8 (9–9) 0–426 0–657
Pre Dias 67–8 (10–7) 72–3 (9–2) 70–9 (4–8) 0–864 0–431
Pre Pulse 68–3 (14–3) 74–3 (9–3) 68–3 (12–4) 0–959 0–394
Sex 6M, 6F 7M, 5F 5M, 7F v#fl 0–67 0–716
Key: CVLT (1–5), California Verbal Learning Test List A Trials 1–5 raw score ; CVLT del, California Verbal Learning Test delayed free
recall List A; CVLT disc, California Verbal Learning Test recognition discrimination score ;’ NART IQ, National Adult Reading Test
predicted pre-morbid full scale IQ; E, Extroversion score from Eysenck Personality Questionnaire-Revised; N, Neuroticism score from
Eysenck Personality Questionnaire-Revised; P, Psychoticism score from Eysenck Personality Questionnaire-Revised; L, Lie score from
Eysenck Personality Questionnaire-Revised; Pre Sys, baseline systolic blood pressure ; Pre Dias, baseline diastolic blood pressure ; Pre Pulse,
baseline pulse rate.
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Experimental condition
Fig. 1. Total number of slides recalled: predicted order effect –
metoprolol (7) impairs andyohimbine (+) improvesmemory relative
to placebo (*). (Jonckheere trend test, Zfl 2–39; P! 0–01.)
Seven days later, memory for the slides and
story was tested. Subjects were credited with
recall of a slide if they described some in-
formation that could only have been known
from viewing that particular slide. As predicted,
yohimbine subjects recalled significantly more
and metoprolol fewer total number of slides
relative to placebo (see Fig. 1). The 11 slide story
can be broken into three phases, slides 1–4
(phase 1) introduce the story and are relatively
neutral, slides 5–8 (phase 2) feature the accident,
1086 R. E. O’Carroll and others
70
80
60
50
40
30
R
ec
o
g
n
it
io
n
 m
em
o
ry
 (
to
ta
l  
%
 c
o
rr
ec
t)
Experimental condition
Fig. 2. Recognition memory: metoprolol (7) impairs and yo-
himbine (+) improves memory relative to placebo (*). (Jonckheere
trend test, Zfl 1–90; P! 0–05.)
where a boy gets knocked down and surgeons
then reattach his severed feet and are emotionally
arousing, slides 9–11 (phase 3) describe the
mother leaving the hospital to pick up her other
child. Previous work has demonstrated that
healthy subjects typically demonstrate height-
ened recall for phase 2. Accordingly, breaking
down the number of slides recalled by story
phase revealed a significant predicted ordered
effect restricted to the central four slide emotion-
al phase of the story (Phase 1 metoprololfl
1–7 (0–9), placebofl 2–4 (0–5), yohimbinefl
2–5 (1–2), Jonckheere Zfl 0–53, NS; Phase 2
metoprololfl 2–0 (0–9), placebofl 2–8 (0–6), yo-
himbinefl 3–3 (0–6), Jonckheere Zfl 1–61, Pfl
0–05; Phase 3 metoprololfl 1–1 (0–9), placebofl
1–1 (0–8), yohimbinefl 1–4 (0–9), Jonckheere Zfl
fi1–58, NS). Analysis of the total scores on
the multiple choice recognition memory test are
presented in Fig. 2. The predicted order effect
was again confirmed, with metoprolol treated
subjects recognizing fewer, and yohimbine
treated subjects correctly recognizing more ma-
terial relative to placebo. Analysis of the
recognitionmemory data by story phase revealed
that all three groups recognized more data from
the central emotional phase of the story (Fig. 3),
and the predicted ordered effect was observed
for phases two and three, but was only stat-
istically significant for phase 3 (Jonckheere Zfl
1–90, P! 0–05).
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Fig. 3. Heightened memory for the emotive (middle) phase of the
story in all three groups (*—*, metoprolol ;U[[[[U, yohimbine ;
D–––D, placebo).
DISCUSSION
In the present study, random allocation to the
three experimental group resulted in good
matching in terms of age, sex, intelligence,
personality, memory functioning and basal
blood pressure and pulse rate. The pharma-
cological intervention was clearly effective as
evidenced by the yohimbine-induced elevations
and metoprolol-induced reductions in mean
heart rate during the slide presentation. One
week later, those subjects who had received
yohimbine recalled significantly more, and meto-
prolol fewer, total number of slides relative to
placebo. Thus, stimulation of the noradrenergic
system resulted in an enhancement and blockade
in a reduction of long-term memory for emo-
tionally valenced material. This effect was
particularly marked for the central most emotive
section of the presentation. The results of the
multiple-choice recognition memory test con-
firmed the findings for free recall, with yohimbine
treated subjects recognizing more material, and
metoprolol subjects recognizing less material
relative to placebo treated subjects. Analysis of
the recognition memory data revealed all groups
demonstrated the normative response, i.e. recog-
nizing more of the central emotional phase of
the story (Cahill & McGaugh, 1995). The
predicted ordered effect of yohimbine, then
placebo followed by metoprolol was evidenced
for phase 2 and was statistically significantly for
Memory and recall of emotional events 1087
phase 3, but not for the initial neutral story
phase. These results cannot be explained by
differences in emotional reactions of the subjects
to the story, as there was no significant difference
between the groups on mean arousal ratings im-
mediately following slide presentation, and this
suggests a pharmacological effect modulating
the encoding of the stimuli.
It is plausible that part of the neural substrate
of heightened memory for emotional material
involves increased sympathetic arousal (often
associated with fear) during the encoding of a
traumatic event. Our findings provide new
support for the view derived from animal
research, that emotional experience activates the
noradrenergic system, thus modulating encoding
so that incident may be better remembered
(Cahill & McGaugh, 1998). Such a mechanism
appears to involve the amygdala (Cahill et al.
1995, 1996) and would have obvious adaptive
value in evolutionary terms, so that potentially
dangerous situations are clearly remembered
and if necessary, avoided in the future. We
propose that this heightened noradrenergic tone
acts to amplify the signal that is to be remem-
bered. The present results have clear clinical
implications. One potential ‘down-side’ of this
modulatory mechanism is that extremely emo-
tional events may be remembered too well by
some individuals, leading to intrusive, distressing
recollections and flashbacks, the central clinical
features of post-traumatic stress disorder (Pit-
man, 1989).
The effect we observed could possibly have
been achieved via the effects of the pharma-
cological manipulation on peripheral mechan-
isms. However, both van Stegeren et al. (1998)
and O’Carroll et al. (1999) failed to find any
effect of peripheral beta blockade on memory
for emotional material in man.
Limitations of the present study are that the
observed between group effects, while statisti-
cally reliable, were small. However, given that
we used single trial dosages of yohimbine and
metoprolol, with no adjustment for body weight
(Peskind et al. 1995) and relatively crude indices
of memory, the positive findings for both free
recall and recognition are impressive. Given that
significant ordered effects were observed for
both recall and recognition data, this suggests
a relatively robust phenomenon. However, it is
extremely unlikely that a single neurotransmitter
system is involved in the enhancement of
memory for emotional events. Clearly, the
hypothalamo–pituitary–adrenal axis is likely to
be involved (Yehuda & Harvey, 1997) as well as
a wide variety of other neurotransmitters,
including NMDA, GABA and endorphins
(O’Brien & Nutt, 1998). However, the available
evidence from experiments using both animals
and man strongly supports the view that the
noradrenergic system plays an important role
(Cahill & McGaugh, 1998).
We found clear evidence of metoprolol im-
pairing memory for emotional material. At-
tempts to replicate the original propranolol
effect (Cahill et al. 1994) have produced con-
flicting results (van Stegeren et al. 1998;
O’Carroll et al. 1999). This may be because the
effect on memory for emotional events is
primarily a beta-1 receptor effect, and propran-
olol is a non-specific beta-1}beta-2 blocker. We
agree with (Cahill et al. (1994) who stated
‘Future research using beta blockers with differ-
ent affinities for beta-1 and beta-2 receptors and
differing effectiveness in passing the blood–brain
barrier should clarify the role of the beta-adren-
ergic system in regulating long-term memory for
emotional experience’ (p. 704). The present
results of enhanced memory for emotional
material also require replication using different
pharmacological manipulations. In particular,
yohimbine does not produce effects specific to
the noradrenergic system (den Boer & Westen-
berg, 1993) and further experiments with phar-
macological agents with greater specificity for
the noradrenergic system are required, as are
dose response studies. However, our findings
provide support for the hypothesis that increased
noradrenergic tone at encoding may be causally
implicated in the phenomena of enhanced
memory for emotional events in man.
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